biotech venture capital

Asia
Pharma

Novartis, Shionogi, ArriVent—Fierce Pharma Asia

Novartis bought an mRNA-coded autoimmune T-cell engager. Shionogi will pay $2 billion to acquire IntraBio. ArriVent's EGFR inhibitor failed in phase 3.
Angus Liu Oct 9, 2026 8:30am
Bubbles in boiling water
Favicon Fierce Biotech

Big Pharma-backed SonoThera sounds off with $125M series B

Jun 10, 2026 10:48am
graphic image of China flags overlapping with US flags
Favicon Fierce Biotech

Will COINS Act kill China biotech licensing boom?

May 26, 2026 3:50pm
Leo Pharma lion

M&A surge triggers high expectations for 2026

Apr 6, 2026 5:00am
MA 2026 2026

Does the Q4 M&A binge foreshadow a boom year for deals in 2026?

Dec 24, 2025 5:00am
A close-up view of a jigsaw puzzle with a missing piece
Favicon Fierce Biotech

Novo Holdings-backed biotech raises $205M to fill gout care gap

Sep 30, 2025 8:00am